Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The role of monoamine oxidase (MAO) inhibitors has expanded in the PD treatment. The present review will summarize the current structureactivity relationship information available on MAOs inhibitors of unrelated families of compounds of oxygen heterocyclic type based on coumarin, chromone and chalcone scaffolds.
As the current hitting-one-target therapeutic strategy has been proved to be quite inefficient in PD, this review will also discuss about the development of multi-target drugs, in which MAO inhibition plays a counter-part, as a novel and promising treatment approach for PD.
Keywords: Parkinson’s disease, MAO inhibitors, SAR, multi-target, coumarins, chromones, chalcones.
Mini-Reviews in Medicinal Chemistry
Title:Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
Volume: 12 Issue: 10
Author(s): A. M. Helguera, G. Perez-Machado, M. N. D.S. Cordeiro and F. Borges
Affiliation:
Keywords: Parkinson’s disease, MAO inhibitors, SAR, multi-target, coumarins, chromones, chalcones.
Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The role of monoamine oxidase (MAO) inhibitors has expanded in the PD treatment. The present review will summarize the current structureactivity relationship information available on MAOs inhibitors of unrelated families of compounds of oxygen heterocyclic type based on coumarin, chromone and chalcone scaffolds.
As the current hitting-one-target therapeutic strategy has been proved to be quite inefficient in PD, this review will also discuss about the development of multi-target drugs, in which MAO inhibition plays a counter-part, as a novel and promising treatment approach for PD.
Export Options
About this article
Cite this article as:
Helguera M. A., Perez-Machado G., D.S. Cordeiro N. M. and Borges F., Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs, Mini-Reviews in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/138955712802762301
DOI https://dx.doi.org/10.2174/138955712802762301 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Indole Alkaloids and Semisynthetic Indole Derivatives as Multifunctional Scaffolds Aiming the Inhibition of Enzymes Related to Neurodegenerative Diseases – A Focus on Psychotria L. Genus
Current Topics in Medicinal Chemistry Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Efficacy of Vitamins B Supplementation on Mild Cognitive Impairment and Alzheimer`s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics Editorial: Exciting Progresses in Stem Cell and Neural Stem Cell Research
Current Molecular Medicine Commentary: Stephen William Hawking (8 January 1942 – 14 March 2018)
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Arachidonic Acid Metabolites in Neurologic Disorders
CNS & Neurological Disorders - Drug Targets Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease
Current Pharmaceutical Design Synopsis on Managment Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development
Current Topics in Medicinal Chemistry Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Midkine and Pleiotrophin in the Treatment of Neurodegenerative Diseases and Drug Addiction
Recent Patents on CNS Drug Discovery (Discontinued)